RE:The competitionWhen evaluated for clinical sensitivity and specificity by comparison to an FDA-authorized molecular diagnostic, BD’s test had a positive percent agreement (PPA)/sensitivity of 84%, and a negative percent agreement (NPA)/specificity of 100% across samples from 226 prospectively enrolled symptomatic patients. Quidel similarly reported PPA/sensitivity and NPA/specificity values of 80% and 100%, respectively.